Gilead Sciences is trading 4% down at $129.81 as investors reassess the company's recent earnings performance, balancing strong top-line growth against significant acquisition-related costs.
- While revenue grew 10% to $7.8 billion, the company reported a substantial GAAP loss driven by $11.2 billion in acquisition-related IPR&D charges.
- Despite an increase in 2026 product sales guidance, some analysts have flagged the stock as overvalued, prompting traders to lock in gains following a recent post-earnings rally.
- The broader biotech sector is currently trading higher, suggesting today's downward move is driven by company-specific valuation concerns rather than macro trends.